Literature DB >> 18794258

Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: assessment of infarct size with 99mTc-annexin V.

Tomoki Doue1, Katsuichi Ohtsuki, Kazuma Ogawa, Masashi Ueda, Akihiro Azuma, Hideo Saji, Harry W Strauss, Hiroaki Matsubara.   

Abstract

UNLABELLED: Administration of erythropoietin (EPO) during or immediately after myocardial ischemia can reduce subsequent myocardial apoptosis, a key phenomenon in myocardial ischemia-reperfusion injury. In this study, we assessed the effect of EPO on (99m)Tc-annexin V myocardial uptake and whether the accumulation of (99m)Tc-annexin V can predict cardiac remodeling and functional deterioration.
METHODS: Eighteen rats with left coronary artery (LCA) occlusion were randomized to receive either an intravenous injection of EPO (EPO group) or saline (nontherapy [nT] group) immediately after release of the occlusion. After 20 min of LCA occlusion and 30 min of reperfusion, the rats were injected with (99m)Tc-annexin V. One hour after (99m)Tc-annexin V injection, the LCA was reoccluded and (201)Tl was injected intravenously, and the rats were sacrificed 1 min later. The heart was removed and sectioned, and dual-tracer autoradiography was performed to evaluate the distribution of the area at risk (defined on the thallium autoradiograph) and the area of apoptosis (defined on the annexin autoradiograph). Adjacent histologic specimens had deoxyuridine triphosphate nick-end labeling (TUNEL) staining to confirm the presence of apoptosis and were compared with autoradiography. Another 16 rats were randomized to EPO and nT groups and underwent echocardiography immediately after release of the LCA occlusion and at 2 and 4 wk after surgery.
RESULTS: The areas of (99m)Tc-annexin V accumulation in the EPO group were smaller than those in the nT group, though the (201)Tl defect areas of these 2 groups were comparable (area ratio, 0.318 +/- 0.038 vs. 0.843 +/- 0.051, P < 0.001, for annexin and 24.8 +/- 2.1 vs. 25.9 +/- 2.6 mm(2), P = NS, for thallium). (99m)Tc-annexin V accumulation correlated with the density of TUNEL-positive cells (r = 0.886, P < 0.001). In the nT group, left ventricular end-diastolic dimension (Dd) increased from baseline at 2 wk by 34.7% +/- 3.8% and remained stable at 34.9% +/- 5.0% at 4 wk after coronary occlusion. In the EPO group, Dd increased by 8.5% +/- 2.1% (P < 0.01 vs. nT at 2 wk) and 13.2% +/- 2.8% (P < 0.01 vs. nT at 4 wk). In the nT group, the left ventricular percentage of fractional shortening decreased by 42.2% +/- 3.4% and 52.9% +/- 3.4% at 2 and 4 wk, respectively, whereas in the EPO group it decreased 9.0% +/- 1.9% at 2 wk (P < 0.01 vs. nT at 2 wk) and 11.1% +/- 6.7% at 4 wk (P < 0.01 vs. nT at 4 wk).
CONCLUSION: This study demonstrated that a single treatment with EPO immediately after release of coronary ligation suppressed cardiac remodeling and functional deterioration. (99m)Tc-annexin V autoradiographs and TUNEL staining confirm that this change is due to a decrease in the extent of myocardial apoptosis in the ischemic/reperfused region.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794258     DOI: 10.2967/jnumed.107.050260

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  Prediction of left ventricular remodelling by radionuclide imaging.

Authors:  Constantinos D Anagnostopoulos; Dennis V Cokkinos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236

2.  Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction.

Authors:  Rosemeire M Kanashiro-Takeuchi; Lauro M Takeuchi; Konstantinos Hatzistergos; Henry Quevedo; Sarah M Selem; Adriana V Treuer; Courtney Premer; Wayne Balkan; Irene Margitich; Yun Song; Qinghua Hu; Joshua M Hare
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

3.  In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [⁶⁸Ga]Annexin A5 and [¹⁸F]FDG PET.

Authors:  Andrei Todica; Mathias J Zacherl; Hao Wang; Guido Böning; Nathalie L Jansen; Carmen Wängler; Peter Bartenstein; Michael C Kreissl; Marcus Hacker; Stefan Brunner; Sebastian Lehner
Journal:  J Nucl Cardiol       Date:  2014-09-05       Impact factor: 5.952

4.  Myocardial infarction: cardioprotection by erythropoietin.

Authors:  Mark I Talan; Roberto Latini
Journal:  Methods Mol Biol       Date:  2013

Review 5.  Radiolabeled apoptosis imaging agents for early detection of response to therapy.

Authors:  Kazuma Ogawa; Miho Aoki
Journal:  ScientificWorldJournal       Date:  2014-10-14

6.  The Role of (99m)Tc-Annexin V Apoptosis Scintigraphy in Visualizing Early Stage Glucocorticoid-Induced Femoral Head Osteonecrosis in the Rabbit.

Authors:  Xiaolong Wang; Yu Liu; Xuemei Wang; Rui Liu; Jianbo Li; Guoliang Zhang; Qiang Li; Lei Wang; Zhigang Bai; Jianmin Zhao
Journal:  Biomed Res Int       Date:  2016-02-16       Impact factor: 3.411

7.  The role of PI3-K/Akt signal pathway in the antagonist effect of CEPO on CHF rats.

Authors:  Zhaoqi Huang; Wei Xu; Jinlei Wu; Shengqiang Chen; Ximing Chen
Journal:  Exp Ther Med       Date:  2018-10-02       Impact factor: 2.447

8.  An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium.

Authors:  Soroush Seifirad
Journal:  Front Physiol       Date:  2014-02-11       Impact factor: 4.566

9.  Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study.

Authors:  Shervin Ziabakhsh-Tabary; Rozita Jalalian; Farzad Mokhtari-Esbuie; Mohammad Reza Habibi
Journal:  Iran J Med Sci       Date:  2014-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.